Changes in plasma fibronectin isoform levels predict distinct clinical outcomes in critically III patients

Biomarker Insights

Volumn 6, Issue , 2011, Pages 59-68

  Peters, John H ^a,b   Grote, Mark N ^c   Lane, Nancy E ^b   Maunder, Richard J ^d  

^a VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d St Charles Health System   (United States)

Author keywords

Acute lung injury; Alternative splicing; Clinical outcomes; Extracellular matrix; Fibronectin

Indexed keywords

FIBRONECTIN; ISOPROTEIN;

ACUTE RESPIRATORY FAILURE; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ALTERNATIVE RNA SPLICING; ARTERIAL OXYGEN TENSION; ARTICLE; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HUMAN; HYPOXEMIA; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SEPSIS; SURVIVAL RATE;

EID: 80053592173     PISSN: 11772719     EISSN: None     Source Type: Journal    
DOI: 10.4137/BMI.S7204     Document Type: Article

References (46)

1. Hynes R. Fibronectins. New York: Springer-Verlag, Inc.; 1990.
2. Matter ML, Ruoslahti E. A signaling pathway from the alpha5 beta1 and alpha(v)beta3 integrins that elevates bcl-2 transcription. J Biol Chem. 2001;276(30):27757-63.
3. Han SW, Roman J. Fibronectin induces cell proliferation and inhibits apoptosis in human bronchial epithelial cells: pro-oncogenic effects mediated by PI3-kinase and NF-kappaB. Oncogene. 2006;25(31):4341-9.
4. Sakai T, Johnson KJ, Murozono M, et al. Plasma fibronectin supports neuronal survival and reduces brain injury following transient focal cerebral ischemia but is not essential for skin-wound healing and hemostasis. Nat Med. 2001;7(3):324-30.
5. Liao YF, Gotwals PJ, Koteliansky VE, Sheppard D, Van De Water L. The EIIIA segment of fibronectin is a ligand for integrins alpha9 beta1 and alpha4 beta1 providing a novel mechanism for regulating cell adhesion by alternative splicing. J Biol Chem. 2002;277(17):14467-74.
6. Shinde AV, Bystroff C, Wang C, et al. Identification of the peptide sequences within the EIIIA (EDA) segment of fibronectin that mediate integrin alpha9beta1-dependent cellular activities. J Biol Chem. 2008;283(5):2858-70.
7. Peters JH, Greasby T, Lane N, Woolf A. Correlations between plasma levels of a fibronectin isoform subpopulation and C-reactive protein in patients with systemic inflammatory disease. Biomarkers. 2009;14(4):250-7.
8. Peters JH, Sporn LA, Ginsberg MH, Wagner DD. Human endothelial cells synthesize, process, and secrete fibronectin molecules bearing an alternatively spliced type III homology (ED1). Blood. 1990;75(9):1801-8.
9. Peters JH, Trevithick JE, Johnson P, Hynes RO. Expression of the alternatively spliced EIIIB segment of fibronectin. Cell Adhes Commun. 1995;3(1):67-89.
10. Peters JH, Maunder RJ, Woolf AD, Cochrane CG, Ginsberg MH. Elevated plasma levels of ED1pp("cellular") fibronectin in patients with vascular injury. J Lab Clin Med. 1989;113(5):586-97.
11. Peters JH, Loredo GA, Chen G, et al. Plasma levels of fibronectin bearing the alternatively spliced EIIIB segment are increased after major trauma. J Lab Clin Med. 2003;141(6):401-10.
12. Cembrowski GS, Mosher DF. Plasma fibronectin concentration in patients with acquired consumptive coagulopathies. Thromb Res. 1984;36(5):437-45.
13. Richards WO, Scovill WA, Shin B. Opsonic fibronectin deficiency in patients with intra-abdominal infection. Surgery. 1983;94(2):210-7.
14. Eriksen HO, Molke-Jensen F, Clemmensen I. Plasma fibronectin concentration in patients admitted to intensive care unit. Haematologia (Budap). 1984;17(1):93-100.
15. Rubli E, Bussard S, Frei E, Lundsgaard-Hansen P, Pappova E. Plasma fibronectin and associated variables in surgical intensive care patients. Ann Surg. 1983;197(3):310-7.
16. O'Connell MT, Becker DM, Steele BW, Peterson GS, Hellman RL. Plasma fibronectin in medical ICU patients. Crit Care Med. 1984;12(6):479-82.
17. Brodin B, Von Schenck H, Schildt B, Liljedahl SO. Low plasma fibronectin indicates septicaemia in major burns. Acta Chir Scand. 1984;150(1):5-11.
18. Oh E, Pierschbacher M, Ruoslahti E. Deposition of plasma fibronectin in tissues. Proc Natl Acad Sci U S A. 1981;78(5):3218-21.
19. Saba TM, Blumenstock FA, Shah DM, et al. Reversal of opsonic deficiency in surgical, trauma, and burn patients by infusion of purified human plasma fibronectin. Correlation with experimental observations. Am J Med. 1986;80(2):229-40.
20. Seeger W, Walmrath D, Heimburger N, Neuhof H. Fibronectin decreases pulmonary vascular permeability under baseline conditions and after administration of arachidonic acid in rabbit lungs. Thromb Res. 1986;44(2):135-46.
21. Vassar MJ, Lewis FR Jr, Chambers JA, et al. Prediction of outcome in intensive care unit trauma patients: a multicenter study of Acute Physiology and Chronic Health Evaluation (APACHE), Trauma and Injury Severity Score (TRISS), and a 24-hour intensive care unit (ICU) point system. J Trauma. 1999;47(2):324-9.
22. Kuhls DA, Malone DL, McCarter RJ, Napolitano LM. Predictors of mortality in adult trauma patients: the physiologic trauma score is equivalent to the Trauma and Injury Severity Score. J Am Coll Surg. 2002;194(6):695-704.
23. Sigurdsson GH, Christenson JT, el-Rakshy MB, Sadek S. Intestinal platelet trapping after traumatic and septic shock. An early sign of sepsis and multiorgan failure in critically ill patients? Crit Care Med. 1992;20(4):458-67.
24. Holzheimer RG, Capel P, Cavaillon JM, et al. Immunological surrogate parameters in a prognostic model for multi-organ failure and death. Eur J Med Res. 2000;5(7):283-94.
25. Parsons PE, Matthay MA, Ware LB, Eisner MD. Elevated Plasma Levels of Soluble TNF Receptors Are Associated with Morbidity and Mortality in Patients with Acute Lung Injury. Am J Physiol Lung Cell Mol Physiol. 2004.
26. Ray DC, Macduff A, Drummond GB, Wilkinson E, Adams B, Beckett GJ. Endocrine measurements in survivors and non-survivors from critical illness. Intensive Care Med. 2002;28(9):1301-8.
27. Matthay MA, Ware LB. Plasma protein C levels in patients with acute lung injury: prognostic significance. Crit Care Med. 2004;32(5 Suppl):S229-32.
28. Navarrete-Navarro P, Ruiz-Bailen M, Rivera-Fernandez R, Guerrero-Lopez F, Pola-Gallego-de-Guzman MD, Vazquez-Mata G. Acute respiratory distress syndrome in trauma patients: ICU mortality and prediction factors. Intensive Care Med. 2000;26(11):1624-9.
29. Hudson LD, Milberg JA, Anardi D, Maunder RJ. Clinical risks for development of the acute respiratory distress syndrome. Am J Respir Crit Care Med. 1995;151(2 Pt 1):293-301.
30. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149(3 Pt 1):818-24.
31. Pepe PE, Potkin RT, Reus DH, Hudson LD, Carrico CJ. Clinical predictors of the adult respiratory distress syndrome. Am J Surg. 1982;144(1):124-30.
32. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818-29.
33. Akaike H. A new look at statistical model identification. IEEE Transactions on Automatic Control. 1974;AU-19:716-22.
34. Venables WN, Ripley BD. Modern Applied Statistics with S. 4th ed. New York: Springer-Verlag; 2002.
35. Venables WN, Ripley BD. MASS version 7.1-11. In.; 2003.
36. Agresti A. Categorical Data Analysis, 2nd ed. New York: Wiley Interscience; 2002.
37. Atabai K, Matthay MA. The pulmonary physician in critical care. 5: Acute lung injury and the acute respiratory distress syndrome: definitions and epidemiology. Thorax. 2002;57(5):452-8.
38. Maunder RJ, Harlan JM, Pepe PE, Paskell S, Carrico CJ, Hudson LD. Measurement of plasma fibronectin in patients who develop the adult respiratory distress syndrome. J Lab Clin Med. 1984;104(4):583-90.
39. Muro AF, Chauhan AK, Gajovic S, et al. Regulated splicing of the fibronectin EDA exon is essential for proper skin wound healing and normal lifespan. J Cell Biol. 2003;162(1):149-60.
40. Peters JH, Ginsberg MH, Bohl BP, Sklar LA, Cochrane CG. Intravascular release of intact cellular fibronectin during oxidant-induced injury of the in vitro perfused rabbit lung. J Clin Invest. 1986;78(6):1596-603.
41. Peters JH, Ginsberg MH, Case CM, Cochrane CG. Release of soluble fibronectin containing an extra type III domain (ED1) during acute pulmonary injury mediated by oxidants or leukocytes in vivo. Am Rev Respir Dis. 1988;138(1):167-74.
42. Zambon M, Vincent JL. Mortality rates for patients with acute lung injury/ ARDS have decreased over time. Chest. 2008;133(5):1120-7.
43. Stapleton RD, Wang BM, Hudson LD, Rubenfeld GD, Caldwell ES, Steinberg KP. Causes and timing of death in patients with ARDS. Chest. 2005;128(2):525-32.
44. Grossman JE. Plasma fibronectin and fibronectin therapy in sepsis and critical illness. Rev Infect Dis. 1987;9 Suppl 4:S420-30.
45. Tan MH, Sun Z, Opitz SL, Schmidt TE, Peters JH, George EL. Deletion of the alternatively spliced fibronectin EIIIA domain in mice reduces atherosclerosis. Blood. 2004;104(1):11-8.
46. Fukuda T, Yoshida N, Kataoka Y, et al. Mice lacking the EDB segment of fibronectin develop normally but exhibit reduced cell growth and fibronectin matrix assembly in vitro. Cancer Res. 2002;62(19):5603-10.